Everest Medicines Announces NEFECON(R)’s Full Approval in South Korea
HONG KONG, Nov 19, 2024 – (ACN Newswire via SeaPRwire.com) – Today, Everest Medicines announced that NEFECON(R) has received full approval from the Ministry of Food and Drug Safety (MFDS) in South Korea, indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio […]















